(Q39842246)

English

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis (English)

1 reference

Europe PubMed Central

15 September 2017

Mycobacterium tuberculosis

0 references

Stefan Kaufmann

17

1 reference

Europe PubMed Central

15 September 2017

author name string

Ronggai Sun

1

1 reference

Europe PubMed Central

15 September 2017

Yasir A W Skeiky

2

1 reference

Europe PubMed Central

15 September 2017

Angelo Izzo

3

1 reference

Europe PubMed Central

15 September 2017

Veerabadran Dheenadhayalan

4

1 reference

Europe PubMed Central

15 September 2017

Zakaria Imam

5

1 reference

Europe PubMed Central

15 September 2017

Erica Penn

6

1 reference

Europe PubMed Central

15 September 2017

Katherine Stagliano

7

1 reference

Europe PubMed Central

15 September 2017

Scott Haddock

8

1 reference

Europe PubMed Central

15 September 2017

Stefanie Mueller

9

1 reference

Europe PubMed Central

15 September 2017

John Fulkerson

10

1 reference

Europe PubMed Central

15 September 2017

Charles Scanga

11

1 reference

Europe PubMed Central

15 September 2017

Ajay Grover

12

1 reference

Europe PubMed Central

15 September 2017

Steven C Derrick

13

1 reference

Europe PubMed Central

15 September 2017

Sheldon Morris

14

1 reference

Europe PubMed Central

15 September 2017

David M Hone

15

1 reference

Europe PubMed Central

15 September 2017

Marcus A Horwitz

16

1 reference

Europe PubMed Central

15 September 2017

Jerald C Sadoff

18

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

2 June 2009

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

27

1 reference

Europe PubMed Central

15 September 2017

33

1 reference

Europe PubMed Central

15 September 2017

4412-4423

1 reference

Europe PubMed Central

15 September 2017

In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The success and failure of BCG - implications for a novel tuberculosis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The SCID mouse mutant: definition, characterization, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Genome plasticity of BCG and impact on vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Disseminated tuberculosis in interferon gamma gene-disrupted mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Genotype and age influence the effect of caloric intake on mortality in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

How can immunology contribute to the control of tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Global Epidemiology of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Advances in tuberculosis vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.048

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.05.048

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39842246&oldid=2139383395"